{"sentence": "Analysts said that Merck & Co. , Eli Lilly & Co. , Warner-Lambert Co. and the Squibb Corp. unit of Bristol-Myers Squibb Co. all benefited from strong sales of relatively new , higher-priced medicines that provide wide profit margins .", "entities": [{"start": 33, "end": 48, "type": "ORGCORP", "argument": "Eli Lilly & Co."}, {"start": 27, "end": 30, "type": "CORPJARGON", "argument": "Co."}, {"start": 120, "end": 123, "type": "CORPJARGON", "argument": "Co."}, {"start": 78, "end": 90, "type": "ORGCORP", "argument": "Squibb Corp."}, {"start": 99, "end": 119, "type": "NAME", "argument": "Bristol-Myers Squibb"}, {"start": 19, "end": 24, "type": "NAME", "argument": "Merck"}, {"start": 99, "end": 112, "type": "NAME", "argument": "Bristol-Myers"}, {"start": 33, "end": 42, "type": "NAME", "argument": "Eli Lilly"}, {"start": 66, "end": 69, "type": "CORPJARGON", "argument": "Co."}, {"start": 99, "end": 123, "type": "ORGCORP", "argument": "Bristol-Myers Squibb Co."}, {"start": 51, "end": 69, "type": "ORGCORP", "argument": "Warner-Lambert Co."}, {"start": 33, "end": 36, "type": "FIRST", "argument": "Eli"}, {"start": 37, "end": 42, "type": "NAME", "argument": "Lilly"}, {"start": 51, "end": 65, "type": "NAME", "argument": "Warner-Lambert"}, {"start": 85, "end": 90, "type": "CORPJARGON", "argument": "Corp."}, {"start": 113, "end": 119, "type": "NAME", "argument": "Squibb"}, {"start": 19, "end": 30, "type": "ORGCORP", "argument": "Merck & Co."}, {"start": 78, "end": 84, "type": "NAME", "argument": "Squibb"}, {"start": 45, "end": 48, "type": "CORPJARGON", "argument": "Co."}]}
